Proteomics International Laboratories Ltd. · ASX:PIQ
Proteomics International Laboratories — Bell Potter Healthcare Conference 2024
12 slides from Proteomics International Laboratories's conference presentation, Nov 20, 2024
Slide 1: Proteomics International to present at the Bell Potter Healthcare Conference
ASX Release 20 November 2024 ASX code: PIQ Proteomics International to present at the Bell Potter Healthcare Conference Proteomics International Laboratories Ltd (Proteomics International; the Company; ASX: PIQ) is pleased to release a copy of the presentation to be provided by Dr Richard Lipscombe
Slide 2: Proteomics International - Bell Potter Healthcare Conference
ASX: PIQ Proteomics International LABORATORIES LTD Bell Potter Healthcare Conference 18-20 November 2024 Dr. Richard Lipscombe Managing Director 1
Slide 3: Disclaimer
Disclaimer ASX: PIQ This Presentation is provided by Proteomics International Laboratories Ltd (Proteomics International, Proteomics, the Company, ASX: PIQ). You should not rely upon anything in this presentation and/or any information obtained from the Company, its Directors or their associates in
Slide 4: Proteomics International Laboratories Ltd
Proteomics International Laboratories Ltd ASX: PIQ A medical technology company at the forefront of predictive diagnostics and precision medicine Commercialising three first-in-class tests driven by a proprietary platform technology: • A novel and accurate test for predicting the onset of chronic ki
Slide 5: Go-to-Market: Synergistic pathways
Go-to-Market: Synergistic pathways ASX: PIQ Direct to consumer/patient (DTC/DTP) and digital marketing pathway – enabled by recent legislation PI establishes Blood collection engaged and PI receives payment reference laboratory samples run Telehealth consult: Promarker Hub Direct patient & clinician
Slide 6: Go-to-Market: Benefits
Go-to-Market: Benefits ASX: PIQ Direct License Establishment and tech transfer risk Low (PI controlled) Medium Time to operations 1H 2025 (Australia and US) To follow Direct market launch Low % (increasing with market Proteomics retained test fee High % validation Out of pocket & PI owned Reimbursem
Slide 7: Multiple Value Drivers in H1 CY25
Multiple Value Drivers in H1 CY25 ASX: PIQ Milestone TARGET Qtr Dec Mar Jun Impact Commercial US reference lab established Key to first US sales and reimbursement First Sales PromarkerD in USA Initiate pathway to significant revenues Australian clinical lab certification established PromarkerD launc
Slide 8: Summary – Exceptional Growth Opportunity
ASX: PIQ • Disruptive, cutting-edge technology & proven in-house Summary – diagnostics platform • Multiple patented products Exceptional • PromarkerD test de-risked, patented, revenue ready Growth • PromarkerEndo and PromarkerEso tests nearing Opportunity market entry • Tests are scalable with high
Slide 9: Supplemental
Supplemental 8
Slide 10: Corporate Overview
Corporate Overview ASX: PIQ Financial and Corporate Corporate Snapshot ASX code PIQ • Top 40 Shareholders hold 41% Market Capitalisation A$91m Cash (30 Sept 2024) (+ R&D Tax Incentive ~$2m H1 FY25) ~A$5.1m • Directors are highly aligned with shareholders holding 13% Share Price (15 Nov 2024) A$0.70
Slide 11: Board of Directors
Board of Directors ASX: PIQ Dr James Williams PhD (Melbourne), MBA (UWA), BSc, Hons (Aberdeen), GAICD, Non-Executive Chair Accomplished manager, director, scientist and investor with experience covering all aspects of life-science technology translation. Involved from startup to commercialisation, i
Slide 12: Contact
Contact ASX: PIQ Dr Richard Lipscombe Dirk van Dissel Managing Director Investor Relations T: +61 8 9389 1992 Candour Advisory E: enquiries@proteomicsinternational.com T: +61 408 326 367 www.proteomicsinternational.com E: dirk@candouradvisory.com.au ASX:PIQ 11
Proteomics International Laboratories — Bell Potter Healthcare Conference 2024 on 6ix